

APPENDIX 3Y – JONATHAN DAVEY + FIONA PAK-POY

Sydney, 29 AUGUST 2024 – Tyro Payments Limited (Tyro) has today released Appendix 3Y forms to correct earlier disclosures of notifiable interests of Mr. Jonathan Davey and Ms. Fiona Pak-Poy. The Appendix 3Y for each of Mr. Davey and Ms. Pak-Poy is attached to this announcement.

The Appendix 3X lodged for Mr Davey on 1 September 2023, inadvertently omitted a second tranche of 22,332 Ordinary Shares held in escrow subject to the repayment of a loan of \$229.16 granted to Mr. Davey. This inadvertent omission resulted from an administrative error.

The Appendix 3Y lodged for Ms Pak-Poy on 14 June 2022, contained a typographical error resulting in the total number of Remuneration Sacrifice Rights held by Ms. Pak-Poy being overstated by 1 right. This error has resulted in the number of shares notified as being held by Ms. Pak-Poy (following the conversion of those Remuneration Sacrifice Rights) currently being overstated by 1 share. This typographical error resulted from an administrative error.

As previously advised on 20 March 2024, Tyro has this year taken measures to ensure compliance with Listing Rule 3.19B by reiterating roles and responsibilities with the relevant employees and incorporating a more detailed cross check when there are Company initiated changes to Directors' interests. Tyro is satisfied that its processes and the measures put in place will reduce the risk of issues such as the historical errors described in this release occurring in the future.

For more information, please contact:

Media:

Gemma Garkut
+61 422 040 559
media@tyro.com

Investors:

Martyn Adlam
+61 452 112 621
investorrelations@tyro.com

Pursuant to Listing Rule 15.5, Tyro confirms this document has been authorised for release by its CEO and Managing Director.

About Tyro

In 2003, Tyro set out to make payments the easiest part of doing business. Today, we're still into business big time, powering more than 71,000 merchants across Australia with in-store, online and on-the-go payment solutions. Working with more than 700 partners, we create seamless payment experiences for hospitality, retail, services and health providers, with integrated banking and lending solutions designed to help unlock the potential of every business. For more information, visit tyro.com.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity.	Tyro Payments Limited
ABN	49 103 575 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jonathan Charles Davey
Date of last notice	15 March 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary Shares held in escrow in an employee share trust subject to the repayment of a loan granted to the employee.
Date of change	<ul style="list-style-type: none">• Date on which error made in notification of disclosable interest – 1 September 2023• Correction made – 29 August 2024

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Interests notified prior to correction:</p> <p><u>Direct interests:</u></p> <ul style="list-style-type: none"> • 297,619 Medipass Service Rights convertible into fully paid ordinary shares. • 297,619 Medipass Performance Rights convertible into fully paid ordinary shares. • 25,314 FY22 Rights convertible into fully paid ordinary shares. • 36,082 FY22 LTI Rights convertible into fully paid ordinary shares. • 159,576 FY23 STI Equity Rights convertible into fully paid ordinary shares. • 159,577 FY23 STI Equity Rights convertible into fully paid ordinary shares. • 1,282,051 FY23 LTI Performance Rights convertible into fully paid ordinary shares. • 1,086,956 FY24 LTI Performance Rights convertible into fully paid ordinary shares. <p><u>Indirect interests:</u></p> <ul style="list-style-type: none"> • 471,148 Ordinary Shares held in escrow in an employee share trust subject to the repayment of a loan granted to the employee.
<p>Class</p>	<p>TYR – Ordinary Shares</p>
<p>Number acquired</p>	<p>22,332 Ordinary Shares held in escrow in an employee share trust subject to the repayment of a loan granted to the employee.</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p>Nil</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>Interests notified after correction:</p> <p><u>Direct interests:</u></p> <ul style="list-style-type: none"> • 297,619 Medipass Service Rights convertible into fully paid ordinary shares. • 297,619 Medipass Performance Rights convertible into fully paid ordinary shares. • 25,314 FY22 Rights convertible into fully paid ordinary shares. • 36,082 FY22 LTI Rights convertible into fully paid ordinary shares. • 159,576 FY23 STI Equity Rights convertible into fully paid ordinary shares. • 159,577 FY23 STI Equity Rights convertible into fully paid ordinary shares. • 1,282,051 FY23 LTI Performance Rights convertible into fully paid ordinary shares. • 1,086,956 FY24 LTI Performance Rights convertible into fully paid ordinary shares. <p><u>Indirect interests:</u></p> <ul style="list-style-type: none"> • 493,480 Ordinary Shares held in escrow in an employee share trust subject to the repayment of a
<p>Nature of change</p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Correction of Appendix 3X released on 1 September 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	<p>Medipass Solutions Pty Ltd (a wholly owned subsidiary of Tyro Payments Ltd agreed to loan Jonathan Davey an amount of \$1,000,787.04 (Loan) to acquire 471,148 shares in Tyro Payments Limited.</p> <p>These shares are currently held by Pacific Custodians Pty Ltd (as trustee for Medipass Employee Share Trust).</p>
Nature of interest	Party to loan agreement.
Name of registered holder (if issued securities)	Pacific Custodians Pty Limited (as trustee for Medipass Employee Share Trust).
Date of change	<ul style="list-style-type: none"> • Correction made – 29 August 2024 • Date on which error made in notification of disclosable interest – 1 September 2023

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small></p>	<p>Interests notified prior to correction: 471,148</p>
<p>Interest acquired</p>	<p>22,332</p> <p>Medipass Solutions Pty Ltd (a wholly owned subsidiary of Tyro Payments Ltd agreed to loan Jonathan Davey an amount of \$229.16 (Loan) to acquire 22,332 shares in Tyro Payments Limited.</p> <p>These shares are currently held by Pacific Custodians Pty Ltd (as trustee for Medipass Employee Share Trust)</p>
<p>Interest disposed</p>	<p>N/A</p>
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small></p>	<p>N/A</p>
<p>Interest after change</p>	<p>Interests notified after correction:</p> <p>Medipass Solutions Pty Ltd (a wholly owned subsidiary of Tyro Payments Ltd agreed to loan Jonathan Davey an amount of \$1,001,016.20 (Loan) to acquire 493,480 shares in Tyro Payments Limited.</p> <p>These shares are currently held by Pacific Custodians Pty Ltd (as trustee for Medipass Employee Share Trust)</p>

Part 3 – ⁺Closed period

<p>Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?</p>	<p>No</p>
<p>If so, was prior written clearance provided to allow the trade to proceed during this period?</p>	
<p>If prior written clearance was provided, on what date was this provided?</p>	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity.	Tyro Payments Limited
ABN	49 103 575 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Fiona Jane Pak-Poy
Date of last notice	23 November 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	<ul style="list-style-type: none"> • Date on which error made in notification of disclosable interest – 14 June 2022 • Correction made – 29 August 2024
No. of securities held prior to change	<p>Interests notified prior to correction:</p> <p><u>Direct interests:</u></p> <ul style="list-style-type: none"> • 233,976 fully paid Ordinary Shares. • 83,000 Options to acquire fully paid ordinary shares. <p><u>Indirect interests:</u></p> <ul style="list-style-type: none"> • 18,182 fully paid Ordinary Shares held by Summit Bend Pty Ltd (jointly controlled by the Director). • 34,546 fully paid Ordinary Shares held jointly by Fiona Jane Pak-Poy & Mr Gregory John Davis as trustees of the PPD Family Trust.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	TYR – Ordinary Shares
Number acquired	N/A
Number disposed	1 Ordinary Share.
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
No. of securities held after change	Interests notified after correction: <u>Direct interests:</u> <ul style="list-style-type: none"> • 233,975 fully paid Ordinary Shares. • 83,000 Options to acquire fully paid ordinary shares. <u>Indirect interests:</u> <ul style="list-style-type: none"> • 18,182 fully paid Ordinary Shares held by Summit Bend Pty Ltd (jointly controlled by the Director). • 34,546 fully paid Ordinary Shares held jointly by Fiona Jane Pak-Poy & Mr Gregory John Davis as trustees of the PPD Family Trust.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Correction of 3Y released on 14 June 2022

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.